About argenx
argenx is a company based in Ghent (Belgium) founded in 2008. argenx has raised $61.9 million across 11 funding rounds from investors including Crédit Agricole, Orbimed and PMV. The company has 355 employees. argenx has completed 1 acquisition, including Forte Biosciences. argenx operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Forge Biologics and Erasca, among others.
- Headquarter Ghent, Belgium
- Employees 355
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website argenx.com
- Social LinkedIn
- Annual Revenue$1.41 B (USD)28as on Dec 31, 2022
- Net Profit-$527.76 M (USD)-32as on Dec 31, 2022
- EBITDA$211.72 M (USD)81as on Dec 31, 2022
- Total Equity Funding$61.9M (USD)
in 11 rounds
- Latest Funding Round$700M (USD), Post-IPO
Mar 2022
- InvestorsCrédit Agricole
& 13 more
- Employee Count355
- Investments & Acquisitions
Funding Insights of argenx
argenx has successfully raised a total of $61.9M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $700 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61.9M
- Total Rounds 11
- Last Round Post-IPO — $700M
- First Round $13.6M
(Sep 2009)
- Investors Count 14
Latest 10 of 11 funding rounds of argenx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $700M | Post-IPO | – | – | – |
| May 2020 | $862M | Post-IPO | – | – | – |
| Nov 2019 | $484M | Post-IPO | – | – | – |
| May 2015 | $1.71M | Grant | – | – | |
| Jan 2015 | $302,892 | Grant | – | – | |
| Nov 2013 | $6.8M | Series B | – | PMV | – |
| Dec 2011 | $37M | Series B | – | Seventure Partners | |
| Nov 2011 | $1.73M | Grant | – | – | |
| Sep 2010 | $2.02M | Grant | – | – | |
| Dec 2009 | $4.5M | Series A | – | Omnes Capital, VIB | – |
14 investors in total: 14 institutional.
Investors in argenx
argenx has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Crédit Agricole, Orbimed and PMV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds are managed across multiple sectors. | 2001 | pmv.eu | Brussels, Belgium | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage life sciences & tech focused VC firm investing in geographies such as Europe | – | erasmusmcfund.nl | Rotterdam, Netherlands | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US | – | seventure.fr | Paris, France | |
Life science focused VC firm investing in startups in Europe | – | biogenerationventures.com | Naarden, Netherlands | |
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US | – | thujacapital.com | Utrecht, Netherlands | |
Private equity firm focused on energy transition and sustainable investments across Europe. | – | omnescapital.com | - | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
PE firm focusing on seed and early stage companies based out of Belgium | – | kbcpe.be | Brussels, Belgium |
Investor details for argenx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of argenx
354 people are tracked at argenx (157 in leadership, 10 in board & advisors, 187 in team); the tracked headcount is 355.
| Name | Role | Group |
|---|---|---|
Karen Massey | Chief Operating Officer | Leadership |
Arjen Lemmen | VP, Corporate Development & Strategy | Leadership |
Srikanth Dasari | Associate Director, Safety Risk Management Lead | Leadership |
Elizabeth Ashcraft | Medical Director, Nephrology Pipeline | Leadership |
Larry Orogun | Senior Medical Director, Clinical Development | Leadership |
Sarthak Pandit | Director, Professional Relations & Independent Medical Education, US Medical Affairs | Leadership |
Filippo Rocca | Director Medical Affairs And Evidence Generation, Partner Markets | Leadership |
Edward Shin | Senior Director, US Commercial And Regulatory Counsel | Leadership |
Srikanth D. | Associate Director, Safety Risk Management Lead | Leadership |
Andrew K. | Associate Director, Clinical Trial Physician | Leadership |
Amrita Datta Chaudhuri | Associate Director Of Medical Writing | Leadership |
Filip Borgions | Chief Technology Innovation Officer | Leadership |
Luc Truyen | Chief Medical Officer | Leadership |
Karl Gubitz | CFO | Leadership |
Sandra Kent | Associate Director Medical Information QA And Operations | Leadership |
Ada Ao-Baslock | Associate Director, Medical Writing | Leadership |
John Haslam | General Manager | Leadership |
Charity Duran | Associate Director, Medical Writing | Leadership |
Karla Redant | Vp, Global Head Trial Operations | Leadership |
Marjolein Kesteloot | Senior Finance Business Partner | Leadership |
334 more people are available in the full profile.
Complete people profiles for argenx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by argenx
argenx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Forte Biosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic solutions for inflammatory skin diseases are developed. | fortebiorx.com | Torrance, United States | 2017 | Jul 2026 | $2.2B |
Complete acquisition details for argenx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of argenx
5 dated milestones of argenx across 18 years, from founding to its latest funding, stage changes and deals.
- Founded argenx is founded.
- Funding First funding round of $13.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $700.0M.
- Acquisition Acquires Forte Biosciences.
Competitors of argenx
argenx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Forge Biologics and Erasca, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of argenx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of argenx
The website of argenx (argenx.com) receives about 62.9K visits a month and ranks #669,034 among all websites worldwide, #747 in Biotechnology and Pharmaceuticals.
- Monthly visits62.9K
▲ 12.1% vs previous month
- Unique visitors23.8K
per month
- Global rank#669,034
among all websites
- Category rank#747
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.6
- Average visit22 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with argenx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| findmecure.com | 100% | 4.2K | #4,771,975 | View details | |
bioworld.com | bioworld.com | 100% | – | #311,180 | – |
| crinetics.com | 100% | 21.7K | #1,355,406 | View details | |
pharmexec.com | pharmexec.com | 100% | – | #565,102 | – |
| pharmatimes.com | 100% | – | #859,223 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for argenx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Argenx
Complete news archive for argenx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to argenx
10 companies that operate in the same segment as argenx (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 | |
Immunotherapeutics for cancer treatment are developed to target solid tumors. | 2017 | San Diego, California, United States | USD 181 M | USD 10 M | 81 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about argenx
argenx was founded in 2008 and raised its 1st funding round 1 year after it was founded.
argenx is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
argenx is a funded company, having raised a total of $61.9M across 11 funding rounds to date. The company's 1st funding round was a Series A of $4.5M, raised on Sep 2009.
argenx has 355 employees.
Annual revenue of argenx is $1.41B as on Dec 31, 2022.
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llamas and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
argenx's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
argenx has made 1 acquisition, including Forte Biosciences.
argenx has 14 investors. Key investors include Crédit Agricole, Orbimed, PMV, VIB, and European Union.